Floatz logo

FLUOROURACILUM

Gastrointestinal Stromal Tumor

TG Therapeutics, Inc.Small moleculePhase 1Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the Gastrointestinal Stromal Tumor cohort.

Asset / SponsorPhaseRating
MIDAZOLAM
Blueprint Medicines Corporation
Phase 4BBB
Regorafenib
Institut Bergonié
Phase 4BBB
Esomeprazole
Erasmus Medical Center
Phase 4BB
CAFFEINE
Markus Joerger
Phase 4BB
Imatinib
M.D. Anderson Cancer Center
Phase 2BB

View all 50 →

Same molecule, other indications

FLUOROURACILUM is also rated in:

colon carcinomaDormant
A
Indicative ·
82 / 100
View asset →
Unresectable or Metastatic Colorectal CancerDormant
BBB
Indicative ·
79 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →